Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 14/20 | 0.58 |
| ▸ | THRB | P10828 | 12/20 | 0.58 |
| ▸ | GSR | P00390 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17549644 | 0.86 | THRA (0.56) | THRATHRBGSREGFR | |
| Hydrochloric Acid SCHEMBL3324195 | 0.85 | THRA (0.54) | THRATHRBGSREGFR | |
| SCHEMBL17549661 | 0.85 | THRA (0.56) | THRATHRBGSREGFR | |
| SCHEMBL9509983 | 0.82 | GSR (0.72) | THRATHRBGSREGFR | |
| SCHEMBL17032000 | 0.81 | ALDH1A1 (0.53) | — | |
| Hydrochloric Acid SCHEMBL10353476 | 0.81 | GSR (0.73) | THRATHRBGSREGFR | |
| SCHEMBL5458640 | 0.79 | GSR (0.64) | THRATHRBGSREGFR | |
| SCHEMBL5565698 | 0.79 | HSD17B3 (0.57) | THRATHRB | |
| SCHEMBL9509517 | 0.79 | THRA (0.60) | THRATHRBGSREGFR | |
| SCHEMBL5081102 | 0.78 | KMT2A (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2016-03-03 | — | — | US | disclosed |
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PHARMACYCLICS INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
| US-20110281850-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2011-11-17 | — | — | US | disclosed |
| US-20070293499-A1 | Intracellular Kinase Inhibitors | MANNKIND CORPORATION (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293499-A1 | Intracellular Kinase Inhibitors | PI4KB, BTK, LTK | THRA 1590/4885THRB 915/4885GSR 4340/4885 |
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | THRA 1590/4885THRB 915/4885GSR 4340/4885 |
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | RNASE1, CDKL2, CDKL1 | THRA 1897/4885THRB 1083/4885GSR 4318/4885 |
| US-20110281850-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | THRA 1590/4885THRB 915/4885GSR 4340/4885 |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | THRA 1590/4885THRB 915/4885GSR 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.